Louis J Denis Selected Research

PF-06263507

1/2021

ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Louis J Denis Research Topics

Disease

8	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 02/2004
6	Neoplasms (Cancer) 01/2021 - 01/2007
1	Neoplasm Metastasis (Metastasis) 11/2015
1	Neutropenia 02/2012
1	Nausea 02/2012
1	Diarrhea 02/2012
1	Carcinogenesis 01/2007

Drug/Important Bio-Agent (IBA)

4	Prostate-Specific Antigen (Semenogelase)IBA 01/2019 - 03/2009
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2007
1	PF-06263507IBA 01/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	AntigensIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 11/2015
1	Irinotecan (Camptosar)FDA LinkGeneric 02/2012
1	Capecitabine (Xeloda)FDA Link 02/2012
1	Cisplatin (Platino)FDA LinkGeneric 12/2009
1	troxacitabineIBA 12/2009
1	XRP6258IBA 01/2009
1	taxaneIBA 01/2009
1	Estrogens (Estrogen)FDA Link 01/2007

Therapy/Procedure

1	Therapeutics 11/2015
1	Chemoprevention 02/2004